Showing 1011-1020 of 1110 results for "".
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operationshttps://modernod.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/CXL Ophthalmics announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Ms. Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was respo
- J&J Vision Receives CE Mark Approval for the ELITA Femtosecond Laser Systemhttps://modernod.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/Johnson & Johnson Vision has received CE Mark approval for the ELITA Femtosecond Laser System for laser vision correction. The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism, via a new lenticular procedure called t
- J&J Vision Presents New Data on Myopia, IOLs, Phacoemulsification, Dry Eye Drops, Vision Science and Refractive Technologieshttps://modernod.com/news/jj-vision-presents-new-data-on-myopia-iols-phacoemulsification-dry-eye-drops-vision-science-and-refractive-technologies-at-arvo/2480839/Johnson & Johnson Vision is presenting 26 poster and podium presentations focusing on myopia, cataract, dry eye, vision science, and refractive research at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Live and Virtual Annual Meeting. Johnson & Johnson Vision poster